Myomo Taps Medical Tech Veteran as CCO to Drive Commercial Growth
Event summary
- Mary-Katherine McClure appointed Chief Commercial Officer at Myomo, effective October 12, 2026.
- McClure brings 20 years of experience in medical technology commercialization, previously at Inspire Medical Systems where she helped grow revenues from $50M to $1B.
- Former CCO Micah Mitchell will stay until December 23, 2026, to ensure a smooth transition.
- McClure granted equity awards totaling 500,000 shares, with performance-based vesting tied to financial metrics and stock price performance by 2029.
The big picture
Myomo's appointment of Mary-Katherine McClure as CCO signals a strategic push to scale its commercial operations, leveraging her proven ability to transform innovative medical technologies into sustainable growth. This move comes as the company seeks to expand market access for its MyoPro product line, which is designed to restore upper-limb functionality for patients with neurological disorders. The transition also highlights the importance of commercial leadership in driving revenue growth in the competitive medical robotics sector.
What we're watching
- Commercial Expansion
- How McClure's track record at Inspire Medical Systems will translate to Myomo's goal of building a nationwide ecosystem of healthcare providers.
- Revenue Scaling
- Whether Myomo can sustain its revenue growth trajectory, which has increased from less than $2M to over $40M under Mitchell's leadership.
- Performance Metrics
- The pace at which Myomo achieves its financial targets tied to McClure's performance-based equity awards, particularly the stock price performance relative to peers by 2029.